Clinical and histopathological characterization of root resorption in replanted teeth: Two case reports.

RATIONALE: The frequency of tooth avulsion is on the rise due to increasing rates of maxillofacial trauma. Avulsed teeth present with varying degrees of root resorption, and are generally asymptomatic; therefore, they often go undiagnosed. The etiopathogenesis of root resorption in replanted teeth following avulsion remains unclear. PATIENT CONCERNS: In case 1, the left upper lateral incisor became loose after 10 years of replantation. In case 2, the patient underwent tooth replantation after external root canal treatment due to tooth dislocation caused by trauma 8 years ago. DIAGNOSIS: According to the medical history, clinical manifestations and imaging studies of the 2 patients, root resorption after replantation was diagnosed. INTERVENTIONS: The teeth extraction was given to one patient. Besides the histological examination of extracted teeth was performed. OUTCOMES: Teeth that underwent pulp treatment presented with external resorption. On the other hand, the tooth that had received no pulp treatment showed both external and internal resorption; residual vital pulp tissue was detected within the pulp cavity. LESSONS: The dental pulp tissues may be involved in the initiation or development of internal resorption. Trauma to the periodontal ligament might play a major role in external resorption, whereas internal tooth resorption may be caused as a result of injury to the residual pulp tissue. Thus, the effective management of these tissues during the treatment of replanted teeth is essential.

The application of hyaluronic acid in bone regeneration.

Hyaluronic acid (HA) exists naturally as an important component of the extracellular matrix (ECM) in the human body. In recent decades, HA has been widely used in bone regeneration, and is currently a popular topic, particularly in the craniofacial and dental fields. From maxilla augmentation to craniofacial bone trauma, there is now a large demand for bone regenerative therapy. Serving as a cell-seeding scaffold or a carrier for bioactive components, hyaluronic acid-incorporated scaffolds and carriers in bone regeneration can be fabricated into either rigid or colloidal forms. Since the type of material used is a critical factor in the biological properties of a scaffold, HA derivatives or HA-incorporated composite scaffolds have shown excellent potential for improving osteogenesis and mineralization. Furthermore, in order to better enhance osteogenesis, local delivery carriers based on hyaluronic acid derivatives, rather than specifically serving as scaffolds, can be established by loading different osteoinductive or osteogenetic components and acquiring different release patterns. Such osteoinductive carriers immobilized on implant surfaces are also effective in improving osseointegration. Thus, as such a competent biomaterial, hyaluronic acid should be considered a promising tool in bone regeneration.

Interleukin-33 and receptor ST2 as indicators in patients with asthma: a meta-analysis.

IL33/ST2 axis activates airway eosinophils that exacerbate airway inflammation. The data was obtained from PubMed, EMBASE, Clinical trial, Cochrane Library, Web of science, CNKI and Wanfang database with time restrictions of 1 Jan, 2000 to 15 Feb, 2016. The meta-analysis was performed using Review Manager 5.2 software. After searching, total 15 documents were included into this meta-analysis, involving in 633 asthma patients and 379 healthy people. The meta-analysis results revealed that the serum IL33 or ST2 level was higher in asthma patients compared to that in healthy people. (P=0.02, 95% CI (7.57, 72.74); P<0.0001, 95% CI (31.27, 91.32)). Compared to healthy people, severe, moderate or mild asthma patients had much higher serum IL33 level. (P<0.00001, 95% CI (87.86, 188.09); P<0.00001, 95% CI (31.93, 72.29); P<0.00001, 95% CI (100.51, 153.08), respectively). The serum ST2 level in different asthma progress included severe or moderate was higher, (P<0.00001, 95% CI (50.76, 76.93); P<0.00001, 95% CI (1.02, 1.79), respectively) but nor mild. (P=0.30, 95% CI (-22.37, 72.61)). The meta-analysis result shown the sputum IL33 was not higher in moderate asthma patients than that in healthy people. (P=0.20, 95% CI (-1.99, 9.52)) The meta-analysis results shown that there were significantly difference between and among two asthma progress, (P<0.00001, 95% CI (14.02, 19.09), severe vs moderate; P<0.00001, 95% CI (0.52, 1.24), moderate vs mild) However, there was no significant differences between severe group and mild group. (P=0.08, 95% CI (-20.95, 336.50)). Serum IL33 and ST2 level is relevant to asthma disease. With asthma disease progress, IL33 and ST2 are increased significantly.

Association of osteopontin polymorphism with cancer risk: a meta-analysis.

To investigate the association of osteopontin gene -443 C>T, -156 G>GG, and -1748 A>G polymorphisms with cancer risk. The Medline, PubMed, PUBMED, EMBASE and Web of Science databases were searched. Meta-analyses were conducted using RevMan 5.2 software. After searching and evaluating the included papers, total 10 documents involved in -443 C>T, 8 papers involved in four articles involved in -156 G>GG and -1748 A>G were included into this meta analysis. There were no significant differences in genotype osteopontin -443 C>T distribution between cancer cases and control (OR=0.98, 95% CI=0.68-1.40, P=0.90; OR=0.90, 95% CI=0.60-1.35, P=0.62; OR=0.98, 95% CI=0.59-1.64, P=0.94; OR=0.87, 95% CI=0.60-1.25, P=0.44, respectively). Meanwhile, no association between osteopontin -1748 A>G polymorphism and tumors under all genetic models. (OR=0.73, 95% CI=0.54-1.00, P=0.05; OR=0.95, 95% CI=0.82-1.10, P=0.48; OR=1.31, 95% CI=0.95-1.81, P=0.10; OR=0.90, 95% CI=0.77-1.06, P=0.20, respectively). However, osteopontin -156 G>GG polymorphism is only partly related to the tumor risk. (GGGG+GGG vs GG model, OR=1.21, 95% CI=1.01-1.46, P=0.04; GGG vs GG model: OR=1.19, 95% CI=1.05-1.35, P=0.008, respectively) osteopontin gene polymorphisms, -443 C>T and -1748 A>G was not associated with cancer risk, but partly associated to tumor risk for -156 G>GG gene polymorphism.